Pharmaceutics / Medical Equipment

The Polish SME from the medical sector established in 2016 gathers a team of neuroscientists, engineers, clinicians, and healthcare innovators. They developed an innovative and the world’s first method for treating memory deficits and other cognitive impairments occurring in the course of Alzheimer’s disease. The method uses a proprietary device for vagus nerve stimulation (tVNS), powered by a unique and patented algorithm that targets brain regions damaged by the disease process. The device influences memory consolidation processes that occur during the REM phase of sleep, supporting cognitive functions in individuals with memory disorders. In 2025, their solution became the first neuromodulation method in the world to receive medical approval in Europe (CE MDR Class II) for the treatment of Alzheimer’s disease. The product is intended for patients with early and moderate stages of Alzheimer’s disease, as well as those with mild cognitive impairment (MCI). It is the first therapy worldwide for Alzheimer’s disease to demonstrate a statistically significant improvement in patients’ clinical condition. The therapy is administered at home, during the night, which increases patient comfort and enables long-term use without the need for hospitalization. The solution builds on the well‑established medical concept of vagus nerve stimulation but introduces a novel approach based on non‑invasive stimulation and a unique, patented neuromodulation algorithm applied during sleep. Existing preclinical studies and medical experiments in patients indicate high therapeutic effectiveness with a low profile of adverse effects—significantly lower than in pharmacotherapy. The company is seeking partners across three key areas to support the international deployment of its product/therapy: - Medical and clinical partners - Distribution and commercial partners - Communication, PR, and awareness‑building partners Commercial agency, distribution services and investment agreements are considered as types of cooperation. Advantages and innovations The solution is a breakthrough, first‑in‑the‑world non‑invasive neuromodulation method for the treatment of Alzheimer’s disease, powered by a patented vagus nerve stimulation algorithm applied during REM sleep. It stands out with its clinically proven effectiveness and an exceptionally low rate of adverse effects compared to pharmacotherapy. The therapy is delivered at home, during the night, ensuring high patient comfort and enabling long‑term use without hospitalization. The product has reached Technology Readiness Level 9 (TRL 9) and holds European medical approval (CE MDR), confirming its readiness for commercialization. The method and device received 7 granted patents (4 US, 2 China, 1 EU). Collaboration with inventors provides access to unique technology, an interdisciplinary R&D team, and extensive experience in developing innovative med‑tech solutions on an international scale. Expected role of a partner 1. Medical and clinical partners Medical centers, clinics, hospitals, and specialized facilities treating patients with cognitive impairments and Alzheimer’s disease. Their role will include implementing the therapy in clinical practice, conducting joint treatment programs, supporting patient qualification, and contributing to real‑world evidence and long‑term monitoring of therapeutic outcomes. 2. Distribution and commercial partners Experienced distributors and commercial partners capable of building and managing sales and distribution networks in their respective countries. Ideal partners should have established market presence in the medical device sector, knowledge of local regulatory pathways, and the ability to scale distribution efficiently. 3. Communication, PR, and awareness‑building partners Companies specializing in PR, media relations, and health communication to support product promotion and raise awareness about innovative approaches to treating cognitive disorders with the Polish product. This includes identifying and engaging Key Opinion Leaders (KOLs), developing communication strategies, and supporting educational and outreach activities.